

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	10/790,027	Confirmation No.	9737
Applicant	John A. Giordano <i>et al.</i>		
Filed	2 March 2004		
TC/Art Unit	1616		
Examiner	F.I. Choi		
Docket No.	48508-00014		
Customer No.	23767		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56(b)**

Mail Stop Amendment
Commissioner for Patents
Alexandria VA 22313

Sir:

In reply to the issues raised by the Examiner in the Office Action mailed 11 August 2004, regarding the Information Disclosure Statement filed 22 March 2004, Applicants' herewith submit on Form PTO/SB/08A the four foreign patents and patent publications and copies of each of the foreign patents and patent publications in their entirety. The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

Applicants are submitting herewith abstracts in English of the two Japanese patents and a concise statement of the relevance of each of these patents to the present application as follows.

Document D5 relates to a composition for alleviating invasion and promoting wound treatment comprising an antioxidant, a metabolic auxiliary factor containing Vitamin B1, B2, B6 and niacin and/or pantothenic acid, a cell growth promotion factor composed of folic acid, Vitamin B12 and/or Vitamin A, a zinc-containing nucleic acid and protein synthesis auxiliary factor


Document D6 relates to a composition composed of a fructose containing sweetener, Vitamin A, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, niacin, calcium pantoate, folic acid, L-isoleucine, sodium L-glutamate, L-theonine, royal jelly and caffeine.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. § 609.

If there are any additional fees due in connection with the filing of this Supplemental Information Disclosure Statement, please charge the fees to undersigned's Deposit Account No. 50-1067. If any extensions or fees are not accounted for, such extension is requested and the associated fee should be charged to our deposit account.

Respectfully submitted,

11 February 2005



Don J. Pelto
Reg. No. 33,754

Preston Gates Ellis & Rouvelas Meeds, L.L.P.
1735 New York Avenue NW, Suite 500
Washington, DC 20006
Telephone: (202) 628-1700
Facsimile: (202) 331-1024

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/790,027	
			Filing Date	2 March 2004	
			First Named Inventor	John A. GIORDANO	
			Art Unit	1616	
			Examiner Name	F.I. Choi	
Sheet	1	of	1	Attorney Docket Number	48508-00014

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	D1	GB 822,127	10-21-1959	Newmark		
	D2	GB 975,387	11-18-1964	Merck & Co Inc.		
	D3	JP 2003-012554	01-15-2003	Azumaguchi et al.		
	D4	JP 2003-59028	06-03-2003	Suzuki et al.		

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D5	Patent Abstracts of Japan 2003-012554	
	D6	Patent Abstracts of Japan 2003-159028	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.